FDMT Q2 2025 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15,000+200.0% YoY

Gross Profit

-$48M-319573.3% margin

Operating Income

-$59M-396373.3% margin

Net Income

-$55M-364386.7% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$474M

Total Liabilities

$53M

Stockholders' Equity

$421M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15,000	$5,000	+200.0%
Gross Profit	-$48M	-$32M	-50.5%
Operating Income	-$59M	-$42M	-40.0%
Net Income	-$55M	-$35M	-56.4%

Revenue Segments

Collaboration And License Revenue

$15,000100%